Conditions and Diseases

The discovery that vitamin D metaboUtes play a much larger biochemical role than just maintaining calcium homeostasis has stimulated a number of groups around the world to develop more economical chemical syntheses for the vitamin D metaboUtes and analogues, which might be useful ki studykig and treating D -related diseases and conditions. Many of these methods are reviewed ki References 139 and 140. 

Parenteral nutrients are used to correct nutritional or fluid deficiencies, as well as to treat certain diseases and conditions. 

Consider the presence of diseases and conditions associated with impairment of small bowel motility... 

Armitage GC Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999 4 1-6. 

Yahoo.com http//dir.yahoo.com/Health/Diseases and Conditions/... 

Characteristics of human diseases and conditions caused by eating seafood contaminated with phycotoxins. 

Authorises expanded access to drugs that are still undergoing investigation for serious diseases and conditions. 

Figure 4.1. Diseases by global importance and by relative importance in low- and medium-low-income countries. Notes The figure shows selected diseases and conditions according to global DALYs lost and the relative weight of each disease or condition in developing countries. If the relative weight is 2, that indicates that that disease is twice as likely to be responsible for a randomly selected lost DALY in low-income countries as in high-income countries. AH data abstracted from World Health Organization (2004).

National lists of essential medicines should be developed for different levels of care and on the basis of treatment guidelines for common diseases and conditions that should be treated at each level. Careful selection of essential medicines is the first step in ensuring access. 

Some of the diseases and conditions selected as indications for the botanical drugs are difficult to study. There are few exciting products to satisfy serious and unmet medical needs. 

The Web site ClinicalTrials.gov also provides patients, family members, health care professionals, and members of the public easy access to information on clinical trials for a wide range of diseases and conditions. The National Institutes of Health (NIH), through its National Library of Medicine, has developed this site in collaboration with all NIH institutes and the FDA. 

The IOM committee reviewed reports about possible associations between herbicide exposures and each of thirty-two diseases and conditions and put the evidence for each association into one of four categories ... 

FIGURE 10—4. Cognitive symptoms are not just associated with schizophrenia, but also with several other disorders, including autism, Alzheimer s disease, and conditions following cerebrovascular accidents (poststroke). 

Creatine has also been shown to be of some benefit in neurological and musculoskeletal diseases and conditions that involve muscle wasting or deterioration of muscle function, such as amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscular dystrophy, Huntington s disease, Parkinson s disease, andMcArdle s disease. 

The justices engaged in an often-spirited debate about whether or not marijuana was an effective treatment for certain diseases and conditions. They declined,... 

The Director of the National Institutes of Health and the Administrator of the Alcohol, Drug Abuse, and Mental Health Administration shall submit to the Board for inclusion in the annual report a report on the rare disease and condition research activities of the Institutes of the National Institutes of Health and the Alcohol, Drug Abuse, and Mental Health Administration the Secretary of the Treasury shall submit to the Board for inclusion in the annual report a report on the use of the credit against tax provided by section 44H of the Internal Revenue Code of 1954 and the Secretary of Health and Human Services shall submit to the Board for inclusion in the annual report a report on the program of assistance under section 5 of the ODA for the development of drugs for rare diseases and conditions. Each annual report shall be submitted by June 1 of each year for the preceding calendar year. 

It is well known that the response to a drug can differ between diseased and nondiseased individuals. For example, the expression of both pro- and anti-inflammatory mediators changes in many diseases and conditions such as rheumatic diseases, myocardial infarction, angina, aging, and obesity [21]. This may have an impact on toxicity and pharmacokinetics, and in particular, when the drug interacts with these mediators. In addition the pharmacokinetics of a drug can be affected by disease in general, a topic that is discussed later in this chapter. 

Other diseases and conditions that can have an effect on the kinetics include cardiac failure, diabetes, and (severe) obesity [35], Dermal disease and lesions can affect the absorption (unintended) of a compound through the skin. Therefore it may be useful to at least include safety endpoints when testing drugs for psoriasis and dermatitis in animal models. 

---